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    1） Objectives and methods of the study
    Although superficial bladder carcinQma can be surgically eliminated by TUR， recurrence
is common． Vari6us attempts have been made to prevent recurrence， but to date an excel－
lent prophylactic method ’with few adverse reactions has not been established．
    We conducted a clinical trial study for Prophylaxis of bladder carcinoma regurrence， using
intravesical instiNation of bleomycin， a dru．cr which cause little・local irritation， in combination
with bestatln， a recently developed immunomodulator．
    Bleomycin was selected on the bases of experimental results． That is， in beagle dogs，
the 1－hour intravesical instillation of bleomycin gained a drug concentration in the bladder wali
of 2．08 ptg／g， whiCh is approximately 4 times higher than that in the intravenous administra－
tion of the same dose． The above bleomycin concentratiori was thought enough to obtain a
good clinical effect．
   A tota！ bf 124 patients were randomly divided into the two treatment groups： An on］y
bleomycin intravesical instillation group （60 mg on each treatment day） （58 patients） and a
bleomycin with bestatin （60 rng per every clay） group （66 patients）． ln the 2－year follow－up
period the recurrence of bladder carcinoma in the two treatment groups was studied．
   2） Analysis of nonrrecurrerice rate by’life－table method and Kaplan－Meier method
   The noR－recurrence rate ef the bladder carcinoma every three months was calcu1ated by
the lifertable and Kaplan－Meier methods． The non－recurrence rate in the bleomycin group was
approximately the same as the rates in．adriamycin or ’niitomy6in reported in the literature．
   In the bleQmycin十bestatin group，． the recurrence rates at．9．months ，and 12 months were
significaRtly （at，1’＝O．09 and P＝O．087．respectivgly） lpwer， ar｝d in addition， even ・the 2－year
overall non－recurren6e rate curves showed a nearly significant diffeyence （P＝O．179）．
Especially in the case of papillary pedunculated tumors， the difference in the non－yecurrene
rate curves was almost statistically siignificant （P ＝O．104）．
   The stratified analysis on the basis of various tumor factors， were as follows．
     （1） Pathological grade
   Although no differences were found in Grades 1 and 2， the bleomycin十bestatin group
 had’a lower recurrence rate in Grade 3 cases （P：：：O．1）．
     （2） Pathological stage
   In the case of pathological stage pTl， the bleomycin十bestatin group had a lower recur－
 rence rate （P〈O．1）．
     （3） Number of tumors
   In single tumors， the bleomycin十bestatin group hacl a significantly lower recurrence
 rate （P〈O．05）．
     （4） Tumor size
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   No statistically significant differences were found in tumor size．
   3） lnvestigation of recurrence rates by analysis of variance and multivariate analysis
   The 2－year observation period was subdivided into・3rmonth periods and the recurrence
rates thereiR were investigated During the first observation year， the bleomycin十bestatin
grouP had a statistically si，cr．nificant lower recurrence rate （P〈O．05）． Although recurrence is
rnost lil〈ely to occer during the first year after TUR， the combined therapy suppressed the
r’?モtrrence rate during the first year． The analysis ofvariance technique revealed that the
bleomycin十bestatin grpup ・had a lower recurrence rate in the case．of the single tumor’ （P〈
O．05）， pTl （P〈O．1） and G3 （P〈O．05） subgroups．
   The multivariate an41ysis revealed that the nymbe；． of ．tumors （P〈O．1）， the pathological
grade （P〈O．1）， the tumor size （P〈O．1） and the administered drug （P〈O．2） had a statistically
sibanificant involvemep’t in recurrence of the tumorr These findings indicate that， in addition
to thc various tumor factors， bestatin lowered tumor recurrerice rate to some degree．
   4） Adverse reactions to the test drugs
   Adverse reactions which could be attributed to bleomycin were observed in 4％ （5／124
patients） of the total patien’ts． There were no sukjective or objective symptoms which were
thou．ffht to be caused by bestatin．
   5） Summary
   In conclusion， even bleomy6in intravesical instillation had a preventive effect on recur－
rence ・of superficial bladcler cancer similar to the reported efficacy of either adriamycin or
mitomydh． Mbre6ver，． the combination of bestatin signi丘cantly enhanced the e田cacy of
bleomycin．
   Especially in the first year of therapy， the superior efficacy of combination therapy was
cleaf工y．．．＄6eln。．．．．T飴．．．Prev6ntiv6．e’fficacY waS p耳rticularly high il■cases of superf主cial l⊃ladder
catcj’窒奄盾狽獅＝f@with an Overall moderate degtee of malignancy （e．g．， charac’terized by a combination
of being a single tumor， pT工and G3）．

































                    らbiological response modifier（以下BRMと略す）





























































Table 1． Concentrations of bleomycin in plasma and bladder tissues
     after intravesical and intravenous administrations to beagle
     dogs
 3 hrs after intravesical
   administretion
（30 mg－potency／le me／dog）
  1 hr after intravenous
   administration
（9tt 26 mg．potency／mう
Dog No． 1 2 3 4 Mean±S．D・
Plas鵬a（μ9－P／・のND． N．D． N．D．0．95 ＿
轡型（㎎・P／9）3川．472．5U．112．08±0．96
Bladder
muscle layer ND． e．66 0，61 N．D． 一
   （je，g－p／g）
1 2 3 4 Mean±S．D．
“．56 O．6“ “． S2 O．64 D．6B±O．IS
O，37 e．28 1，00 O，5e O，5G±O．32
0．23 0．28 0．2S NID． 一
N．D．：could not be detected
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週間前後よりble・mycin 60 mg／EL 7日問連続膀胱
内注入をおこなった．（以下連続二三と略す）．その後




























































































Table 2． Patient data
Registered Cases 146
Excluded Cases 22
           Not superficial eancer 2
           Not first therapy 3
           Non－transitional carcinoma 2
           Higher than stage B2（unresectable pT2） 1Reasons for Exclusion
           Incemplete tumor “e＄ection 1
           1nsufficient no． of intravesical instillationsl
           No post－TUR cystoseopic examination 4
           Multiple cancers 8
Analyzed Case＄ 124
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Tab！e 3． Patient back．crround factors
Backgreund Factor
Group Plneem．yc．ip BleOnyYCin Tetat
   十Bestatin     enly Background Factor
Group Bleemycin BleoMY¢in Totat
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 Ble・mycin＋Bestatin併用群内では， G1， G2， G3
の3二間に差は認められなかった．しかし，bleomy－
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Table 4．Results of “Analysis of Variance” of frequency of tumor
recurrence as function of time．period
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Time Period ：at S levels．ol ．e“ehy 3 mo，
’through 24th month
Time Period’： at 2 levels of every・3’ mo：
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Effect of drug on frequency of recurrence as function of variQus
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Fig． 16．Multivariate analysis of effect of background factors on
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Fig． 17．Multivariate analysis of effects of background factors on













































































O Befere 3 6 9 12 15 le 21 24（months）




























e eefore 36 9 12 15
Follew－Up Time





















O Before 1 E 12


























n＝S    n＝3  n＝2
O Befere 36 9 12 fs
Follow－Up Time
IS 21 24（menths）


































Table 5． Results of clinical study on bladder cancer
RepertersReference Treatment Pathelegical Non－Recurrenee Rate｛％）Stage l yeer ’@2 Year
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       Jap． J． Urel．Takayasu et al．      69， 663－678， 蓄野78
       J， Urel．，Loening et al．      123， 29－31， 197S
       Jap． J． Urot．．Maru et al，      14， 79e－SOT， ISe3
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